Dupixent EOE denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent eoe are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Dupixent in EoE

Prior authorization (PA) for Dupixent in eosinophilic esophagitis is a standard UHC utilization-management requirement, not a coverage denial. However, when a PA is denied — or when a claim is denied because a PA was not obtained before dispensing — the result is a coverage denial that must be appealed through the same formal process as any other denial. PA denials for EoE typically occur because: the submission did not document that required prior therapies were tried, the diagnosis was not confirmed with biopsy results, or the clinical information submitted did not address each criterion in UHC's PA criteria for dupilumab-EoE.

## Why This Denial Is Appealable

PA criteria must be based on clinical evidence and cannot be more restrictive than the FDA-approved labeling. If the patient genuinely meets the PA criteria and the denial occurred due to incomplete documentation, the appeal is a documentation exercise. If the PA criteria themselves are being applied in a way that conflicts with standard of care or the FDA label, that is grounds for external review.

## Federal Appeal Framework

• Peer-to-peer review: Request this immediately. The prescriber speaks directly with UHC's reviewing physician and can clarify documentation gaps in real time. Many PA denials reverse here.
• Internal appeal: File within the deadline on the denial notice. Submit complete documentation addressing every PA criterion.
• External review (ACA §2719 / ERISA §503): Available after one internal appeal level is exhausted. File within approximately four months of the final internal denial (confirm exact date on the denial notice). Particularly valuable if UHC's PA criteria conflict with the FDA label or applicable specialty guidelines.
• Expedited PA and appeal: If the patient is currently symptomatic and delay poses a health risk, request expedited PA review and, if denied, expedited external review.

## Documentation to Gather

1. Confirmed EoE diagnosis: Endoscopic biopsy pathology report with eosinophil counts, gastroenterologist's note. 2. Prior therapy documentation: Records for every EoE treatment tried before Dupixent — dates started, dates stopped, reason for discontinuation or inadequate response. 3. Current clinical status: Recent chart notes, symptom severity assessment, most recent endoscopic or imaging findings. 4. Prescriber PA support letter: A letter that goes through UHC's PA criteria point by point, citing chart entries for each.

## Criteria-Mapping Structure

Download UHC's current prior authorization criteria for dupilumab-EoE (available through the UHC Provider Portal). Copy each criterion verbatim into a table. In the adjacent column, cite the specific chart note, lab value, date, or prescriber statement that satisfies it. Submit this table as a cover document with the full supporting records behind it. This format shortens review time and closes the gap that caused the initial denial.